Rhythm Pharmaceuticals Q3 2026 Earnings Conference Call - RHYTHM PHARMACEUTICALS INC

Explicit Guidance:

• Revenue: Q3 2026 global net product sales of $92.1 million (29% sequential growth). U.S. launch is the primary driver of sequential growth, with international revenue of $24.7 million.
• Operating Expenses (Non-GAAP): Updated annual guidance for FY2026 to approximately $360–$380 million.
  • Non-GAAP R&D: $165–$175 million (midpoint reduced by $15 million vs. prior due to timing shifts of late 2026 activities to early 2027).
  • Non-GAAP SG&A: $195–$205 million.
• R&D Timing: Bioequivalent, food effect, drug-drug interaction, and hepatic impairment studies for Bivomelagon completed; Phase 3 trial in PWS expected to initiate in 2027. Two global Phase 3 trials (HO and PWS) for Bivomelagon expected to be "well underway" next year (FY2027).
• Cash & Liquidity: Q3 2026 ending cash, cash equivalents, and short-term investments of ~$320 million (excluding term loan proceeds and initial LG Chem payment). Management expects this cash is sufficient to fund operations for at least 24 months.
• Financing & Payments:
  • $350 million total payments to LG Chem over four years: $70M (due 15 days from closing), $100M (Sept 2027), $200M (Dec 2028), $80M (Sept 2029).
  • $250 million drawn immediately from a new 5-year term loan facility (with $250M optional availability); total facility $750M. Interest rate at SOFR + 4.6%.
  • Additional potential $200M commercial milestone to LG Chem if $3B in annual sales is achieved.
• Share Count: Weighted average common shares outstanding ~69 million. Net loss per share (basic and diluted) of $0.61, including $1.0M accrued dividends on convertible stock.

Business-Segment Outlook:

• U.S. Acquired Hypothalamic Obesity (HO): Launch in Q3 2026 (2nd full quarter) showing strong, consistent patient demand and broadening prescriber base (>500 prescribers, ~200 first-time in Q3). 75% of approvals via prior authorization; >80% approved within 60 days. Expect steady uptake in Q4 2026 with no expected slowdown.
• Japan: Commercial launch initiated October 14, 2026. First commercial patients on treatment. Expected to become the second-largest market (population est. 5,000–8,000). Identified >1,000 eligible patients pre-launch. First-year revenue constrained by 2-week supply restrictions; expected to accelerate in years 2 and 3 (2027–2028) when restrictions lift (Nov 2027). Price set at $2,200/vial (60% of U.S. WAC) for a 10-year period.
• Europe: Launches expected in 2027, starting with Germany, followed by France, UK, Spain, and Netherlands. Estimated patient population ~10,000. Reimbursement dossiers submitted in multiple countries; early access programs in France/Italy treated >100 patients.
• Prader-Willi Syndrome (PWS): Six-month Phase 3 trial expected to initiate in 2027 with hyperphagia (HQCT) as primary endpoint. BMI reduction expected to be included in label but not primary endpoint. Strategy includes developing both Bivomelagon and next-generation therapies (7.8) for optimal combination approaches.
• Bardet-Biedl Syndrome (BBS): Business continues to grow; dedicated territory manager team focused on BDs.

Market and Competitive Outlook:

• Demand Trends: Expect sustained growth in prescribers and patient identification. Early dynamics show 15% of prescriptions from patients with injury <2 years ago; >33% from patients with injury >10 years ago.
• Payer Access: Current payer policies cover ~60% of Medicaid and ~75% of commercial lives in the U.S. Expect additional policies to be established by end of 2026. Access speed (Rx to approval) expected to remain consistent with current pace (~60 days), similar to BBS launch.
• Competitive Landscape: PWS has only one approved therapy (BICAT); Acquired HO had no approved therapies prior to MCVRI. Expect payers to follow label-based utilization (hyperphagia endpoint for PWS approval).
• Supply/Distribution: Japan imposes a 2-week supply limit for the first year; restriction lifts Nov 2027 to allow up to 3-month supply.

Macro / Industry Outlook:

• Regulatory Environment: Anticipate regulators to follow precedent set by BICAT approval regarding trial duration and endpoints for PWS (6-month hyperphagia).
• Market Structure: Japan's centralized healthcare system and national coverage viewed as favorable for rare disease adoption compared to fragmented European markets.
• Pricing: Long-term pricing in Japan is fixed for 10 years. U.S. pricing dynamics expected to hold with steady uptake.

Strategic Initiatives:

• Licensing (LG Chem): Amendment signed to buy down cross-portfolio royalty from 5–7% to 1% (flat) upon U.S. approval of Bivomelagon in HO. Investment of $350M over 4 years aligns incentives to develop best treatment regardless of indication.
• Financing: Secured $750M term loan facility (5-year, no equity component, no exit fee) and amended revenue interest financing agreement to remove debt-like covenants.
• Clinical Development:
  • Phase 3 Bivomelagon HO study: Screening to begin end of 2026; first patient dose Jan 2027.
  • Phase 3 Bivomelagon PWS study: Initiation expected in 2027.
  • Next-generation therapies (7.8) to be developed in parallel with Bivomelagon for PWS and HO.
• Portfolio Expansion: Goal to expand genetic indications list in 2027; full portfolio update planned for 2027.
• Geographic Expansion: Establishing Japan presence (50+ employees); advancing European market access for 2027 launches.

Risks and Headwinds to Outlook:

• Japan Launch Trajectory: First-year revenue constrained by 2-week supply limit; acceleration delayed until restrictions lift in Nov 2027.
• PWS Approval Risk: High placebo rate for hyperphagia; 6-month trial duration chosen to move beyond placebo effect. Regulatory acceptance of 6-month data remains a variable, though precedent is being set.
• Payer Policies: Ongoing need to expand prior authorization policies; pace of P&T meetings could delay coverage expansion.
• Diagnosis Barriers: Acquired HO requires clinical diagnosis and education to distinguish from other obesity causes; conversion from suspected to confirmed diagnosis takes time.
• Supply Chain: Previous decision to start with Bivomelagon in PWS was partly driven by supply/CMC availability of the alternative asset.

Management Tone on the Future:

• Confidence: Highly bullish and confident. Management describes the Q3 launch as "strong" and "excellent." Expresses "growing conviction" in the magnitude of the global HO opportunity.
• Strategic Shift: "Fully aligned" incentives with LG Chem to prioritize science over royalty structures; view as a "bullish investment" in the core MC4R franchise.
• Outlook: Expectations for 2027 include accelerating development of next-gen assets, initiating multiple pivotal trials, and international commercial acceleration. Tone suggests "strong financial position" with sufficient capital flexibility for 24+ months.

Miscellaneous:

• Patient Metrics: >700 patient start forms received in first two quarters of U.S. launch. Age distribution evenly split; 20% from ages 4–12.
• Prescriber Growth: >500 prescribers active; ~25% wrote 2+ prescriptions (up from 20% in Q2). 80% of prescribers are endocrinologists (even split adult/pediatric).
• Japan Team: 50+ employees established; 300 of 350 priority hospitals engaged; >1,000 eligible patients identified.
• R&D Milestones: Development milestone associated with CHI program recognized in Q3 expenses; other studies completed to de-risk Bivomelagon.